Muscle selection and dosing in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in real-world practice
DOI:
https://doi.org/10.2340/jrm.v57.42605Keywords:
abobotulinumtoxinA, botulinum toxin A, goal attainment scaling, rehabilitationAbstract
Objective: Describe abobotulinumtoxinA (aboBoNT-A) dosing parameters in the real-world management of lower limb spasticity (LLS).
Methods: Prospective, observational study (NCT04050527) following ambulatory adults with unilateral LLS treated with aboBoNT-A.
Results: The effectiveness population included 384 adults with LLS. Across the study, total lower limb doses were higher in patients who received only lower limb injections (n = 131, median 771U) than those who also received ≥ 1 upper limb injection (n = 253, 567U). Total doses increased over subsequent cycles in both subgroups. Six muscles (gastrocnemius medial and lateral heads, soleus muscle, tibialis posterior, flexor digitorum longus, and flexor hallucis longus) were identified as the main targets for the treatment of LLS; other lower limb muscles were injected in fewer than 15% of patients. The most frequent therapy interventions (mean ± SD of 1.8 ± 1.3h/week with a qualified therapist and 5.3 ± 5.9h/week self-rehabilitation in Cycle 1) were task-specific practice, passive stretch, strength training, and positioning.
Conclusions: This study demonstrates how a diversity of muscle patterns are currently treated in routine practice where the primary goal was related to the lower limb and highlights important issues for further debate, such as potential underdosing and the need to balance upper and lower limb priorities when devising a treatment plan.
Downloads
References
Pundik S, McCabe J, Skelly M, Tatsuoka C, Daly JJ. Association of spasticity and motor dysfunction in chronic stroke. Ann Phys Rehabil Med 2019; 62: 397–402.
https://doi.org/10.1016/j.rehab.2018.07.006 DOI: https://doi.org/10.1016/j.rehab.2018.07.006
Sheffler LR, Chae J. Hemiparetic gait. Phys Med Rehabil Clin N Am 2015; 26: 611–623.
https://doi.org/10.1016/j.pmr.2015.06.006 DOI: https://doi.org/10.1016/j.pmr.2015.06.006
Li S. Ankle and foot spasticity patterns in chronic stroke survivors with abnormal gait. Toxins 2020; 12: 646.
https://doi.org/10.3390/toxins12100646 DOI: https://doi.org/10.3390/toxins12100646
Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016; 86: 1818–1826.
https://doi.org/10.1212/WNL.0000000000002560 DOI: https://doi.org/10.1212/WNL.0000000000002560
Royal College of Physicians (UK). Spasticity in adults: management using botulinum toxin; 2018. Available from: https://www.rcplondon.ac.uk/guidelines-policy/spasticity-adults-management-using-botulinum-toxin.
Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, et al. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: randomized trial and extension. Neurology 2017; 89: 2245–2253.
https://doi.org/10.1212/WNL.0000000000004687 DOI: https://doi.org/10.1212/WNL.0000000000004687
Esquenazi A, Zorowitz RD, Ashford S, Beneteau M, Maisonobe P, Hannes C, et al. Longitudinal goal attainment with repeat injections of abobotulinumtoxinA in adults with lower limb spasticity: results from a prospective observational study. Arch Phys Med Rehabil 2024 Nov 20 [Online ahead of print].
https://doi.org/10.1016/j.apmr.2024.10.017 DOI: https://doi.org/10.1016/j.apmr.2024.10.017
Fheodoroff K, Bhidayasiri R, Jacinto LJ, Chung TM, Bhatia K, Landreau T, et al. Ixcellence Network(R): an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. Funct Neurol 2017; 32: 103–110.
https://doi.org/10.11138/FNeur/2017.32.2.103 DOI: https://doi.org/10.11138/FNeur/2017.32.2.103
Ashford S, Jackson D, Turner-Stokes L. Development of a measure of therapy provision for spasticity management in the paretic lower limb: the Leg Therapy recording Schedule (LegTS). Disabil Rehabil 2018; 40: 479–485.
https://doi.org/10.1080/09638288.2016.1258435 DOI: https://doi.org/10.1080/09638288.2016.1258435
Turner-Stokes L, Jacinto J, Fheodoroff K, Brashear A, Maisonobe P, Lysandropoulos A, et al. Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: first cycle results from the ULIS-III Study. J Rehabil Med 2021; 53: 1–9.
https://doi.org/10.2340/16501977-2770 DOI: https://doi.org/10.2340/16501977-2770
Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, et al. Correction: Field, M. et al. AbobotulinumtoxinA (Dysport(R)), OnabotulinumtoxinA (Botox(R)), and IncobotulinumtoxinA (Xeomin(R)) neurotoxin content and potential implications for duration of response in patients. Toxins 2019; 11: 535.
https://doi.org/10.3390/toxins11020115 DOI: https://doi.org/10.3390/toxins11020115
Jacinto J, Varriale P, Pain E, Lysandropoulos A, Esquenazi A. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in spasticity. Front Neurol 2020; 11: 388.
https://doi.org/10.3389/fneur.2020.00388 DOI: https://doi.org/10.3389/fneur.2020.00388
Taylor M, Bahroo L, Dougherty C. Practice management: botulinum toxin billing & coding update. Practical Neurology 2022 [accessed December 2024]. Available from: https://practicalneurology.com/articles/2022-may/practice-management-botulinum-toxin-billing-coding-update.
Francisco GE, Balbert A, Bavikatte G, Bensmail D, Carda S, Deltombe T, et al. A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: an international group consensus. J Rehabil Med 2021; 53: jrm00134.
https://doi.org/10.2340/16501977-2753 DOI: https://doi.org/10.2340/16501977-2753
Turner-Stokes L, Ashford S, Esquenazi A, Wissel J, Ward AB, Francisco G, et al. A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework. Eur J Phys Rehabil Med 2018; 54: 605–617.
https://doi.org/10.23736/S1973-9087.17.04808-0 DOI: https://doi.org/10.23736/S1973-9087.17.04808-0
Esquenazi A, Lee S, Mayer N, Garreta R, Patel A, Elovic E, et al. Patient registry of spasticity care world: data analysis based on physician experience. Am J Phys Med Rehabil 2017; 96: 881–888.
https://doi.org/10.1097/PHM.0000000000000781 DOI: https://doi.org/10.1097/PHM.0000000000000781
Rosales RL, Chia NVC, Kumthornthip W, Goh KJ, Mak CS, Kong KH, et al. Botulinum toxin A injection for post-stroke upper limb spasticity and rehabilitation practices from centers across Asian countries. Front Neurol 2024; 15: 1335365.
https://doi.org/10.3389/fneur.2024.1335365 DOI: https://doi.org/10.3389/fneur.2024.1335365
Esquenazi A, Zorowitz RD, Ashford S, Maisonobe P, Page S, Jacinto J. Clinical presentation of patients with lower limb spasticity undergoing routine treatment with botulinum toxin: baseline findings from an international observational study. J Rehabil Med 2023; 55: jrm4257.
https://doi.org/10.2340/jrm.v55.4257 DOI: https://doi.org/10.2340/jrm.v55.4257
Downloads
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Richard D. Zorowitz , Jorge Jacinto , Stephen Ashford , Mathieu Beneteau , Pascal Maisonobe , Christian Hannes, Alberto Esquenazi
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
